Unknown

Dataset Information

0

Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series.


ABSTRACT: INTRODUCTION:Patients receiving statin therapy for dyslipidaemia often require treatment with an additional agent to control triglyceride levels. Options for add-on therapy include fibrates and omega-3 fatty acids. This case series describes the effects of switching add-on therapy from fenofibrate to icosapent ethyl (the ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid) on patient lipid profiles. METHODS:This was a retrospective analysis of patient records from a private medical practice in western New York. Statin-treated patients with dyslipidaemia who had been treated with fenofibrate and later switched to icosapent ethyl were selected for analysis. Lipid profiles before and after the switch to icosapent ethyl were compared. RESULTS:The records of five patients were analysed. All patients had hypertension and were overweight, male, and at high cardiovascular risk. After the switch to icosapent ethyl (treatment duration 3.9-5.8 months), triglyceride levels decreased in four patients, and low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and total cholesterol levels decreased in all patients. High-density lipoprotein levels increased in four patients. Icosapent ethyl was well tolerated. CONCLUSIONS:Switching from fenofibrate to icosapent ethyl as add-on to a statin therapy due to clinical need may provide an option for patients to maintain or improve lipid parameters.

SUBMITTER: Castaldo RS 

PROVIDER: S-EPMC4801984 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Switching statin-treated patients from fenofibrate to the prescription omega-3 therapy icosapent ethyl: a retrospective case series.

Castaldo Richard S RS  

Drugs & therapy perspectives : for rational drug selection and use 20160308


<h4>Introduction</h4>Patients receiving statin therapy for dyslipidaemia often require treatment with an additional agent to control triglyceride levels. Options for add-on therapy include fibrates and omega-3 fatty acids. This case series describes the effects of switching add-on therapy from fenofibrate to icosapent ethyl (the ethyl ester of the omega-3 fatty acid, eicosapentaenoic acid) on patient lipid profiles.<h4>Methods</h4>This was a retrospective analysis of patient records from a priva  ...[more]

Similar Datasets

| S-EPMC4957603 | biostudies-literature
| S-EPMC4472650 | biostudies-literature
| S-EPMC6525216 | biostudies-literature
| S-EPMC8844997 | biostudies-literature
| S-EPMC9524612 | biostudies-literature
| S-EPMC4230929 | biostudies-literature
| S-EPMC7537800 | biostudies-literature
| S-EPMC5470410 | biostudies-literature
| S-EPMC7537801 | biostudies-literature
| S-EPMC5828468 | biostudies-literature